Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Stefania Belli"'
Autor:
Stefania Belli, Daniela Esposito, Alessandra Allotta, Alberto Servetto, Paola Ciciola, Ada Pesapane, Claudia M. Ascione, Fabiana Napolitano, Concetta Di Mauro, Elena Vigliar, Antonino Iaccarino, Carmine De Angelis, Roberto Bianco, Luigi Formisano
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have been approved in combination with endocrine therapy (ET) to treat estrogen receptor-positive (ER+) metastatic breast cancer (BC). However, drug resistance represents the leading cause
Externí odkaz:
https://doaj.org/article/cdae9eaf368147059fb77d8291facd77
Autor:
Iolanda Scognamiglio, Lorenza Cocca, Ilaria Puoti, Francesco Palma, Francesco Ingenito, Cristina Quintavalle, Alessandra Affinito, Giuseppina Roscigno, Silvia Nuzzo, Rosario Vincenzo Chianese, Stefania Belli, Guglielmo Thomas, Timo Schomann, Alan Chan, Maria Patrizia Stoppelli, Gerolama Condorelli
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 28, Iss , Pp 17-31 (2022)
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. TNBC progression is sustained by recruitment of a strong tumor microenvironment (TME) mainly composed of cancer-associated fibroblasts (CAFs) able to endorse tumor hal
Externí odkaz:
https://doaj.org/article/26bca4025edc49b0acd8b1782fa15af9
Autor:
Marcello Monti, Viviana De Rosa, Francesca Iommelli, Maria Vincenza Carriero, Cristina Terlizzi, Rosa Camerlingo, Stefania Belli, Rosa Fonti, Giovanni Di Minno, Silvana Del Vecchio
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 8, p 2350 (2018)
Neutrophil extracellular traps (NETs), in addition to their function as a host defense mechanism, play a relevant role in thrombus formation and metastatic dissemination of cancer cells. Here we screened different cancer cell lines endogenously expre
Externí odkaz:
https://doaj.org/article/acc75222aed5471cb8af767d693cb895
Autor:
Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Muñoz-Mateu, Begoña Bermejo, Mireia Margeli Vila, Antonio Antón, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesús Herranz, Daniel Fernández-García, Rosalía Caballero, José Antonio López-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martín
Publikováno v:
Clinical Cancer Research. 29:1557-1568
Purpose: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this res
Autor:
Miguel Martín, Nicholas Turner, Luigi Formisano, Roberto Bianco, José Antonio López-Guerrero, Rosalía Caballero, Daniel Fernández-García, Jesús Herranz, Yuan Liu, Bella Nissenbaum, Laura Murillo, Antonio Antón, Mireia Margeli Vila, Begoña Bermejo, Montserrat Muñoz-Mateu, Javier Pascual, Eva Maria Ciruelos Gil, Manuel Ruiz-Borrego, Antonio Fernandez-Serra, Miguel Gil-Gil, Christoph Zielinski, Stefania Belli, Ángel Guerrero-Zotano
Purpose:In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4244600429ae7a873666e211efa710ec
https://doi.org/10.1158/1078-0432.c.6533095.v2
https://doi.org/10.1158/1078-0432.c.6533095.v2
Autor:
Miguel Martín, Nicholas Turner, Luigi Formisano, Roberto Bianco, José Antonio López-Guerrero, Rosalía Caballero, Daniel Fernández-García, Jesús Herranz, Yuan Liu, Bella Nissenbaum, Laura Murillo, Antonio Antón, Mireia Margeli Vila, Begoña Bermejo, Montserrat Muñoz-Mateu, Javier Pascual, Eva Maria Ciruelos Gil, Manuel Ruiz-Borrego, Antonio Fernandez-Serra, Miguel Gil-Gil, Christoph Zielinski, Stefania Belli, Ángel Guerrero-Zotano
Descriptive analysis of extreme responders subpopulation, according to clinical characteristics and tumor subtype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cbddfe72831b8ae282577cf46fdcaa2
https://doi.org/10.1158/1078-0432.22633135
https://doi.org/10.1158/1078-0432.22633135
Autor:
Miguel Martín, Nicholas Turner, Luigi Formisano, Roberto Bianco, José Antonio López-Guerrero, Rosalía Caballero, Daniel Fernández-García, Jesús Herranz, Yuan Liu, Bella Nissenbaum, Laura Murillo, Antonio Antón, Mireia Margeli Vila, Begoña Bermejo, Montserrat Muñoz-Mateu, Javier Pascual, Eva Maria Ciruelos Gil, Manuel Ruiz-Borrego, Antonio Fernandez-Serra, Miguel Gil-Gil, Christoph Zielinski, Stefania Belli, Ángel Guerrero-Zotano
Evaluation of volasertib effects on tumor spheroid growth and on the activation of signal transduction pathways in PalboR and FPR cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::302e51e3145fb52d37a7c4806e0ed4d2
https://doi.org/10.1158/1078-0432.22633174
https://doi.org/10.1158/1078-0432.22633174
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges
Autor:
Alberto Servetto, Daniela Esposito, Roberto Ferrara, Diego Signorelli, Stefania Belli, Fabiana Napolitano, Antonio Santaniello, Paola Ciciola, Luigi Formisano, Roberto Bianco
Publikováno v:
Biochimica et biophysica acta. Reviews on cancer. 1877(6)
The Rearranged during Transfection (RET) oncogene has been extensively investigated in solid malignancies, particularly thyroid cancer and non-small cell lung cancer (NSCLC), and represents an attractive therapeutic target. RET rearrangements occur i
Autor:
Roberta Marciano, Alberto Servetto, Concetta Di Mauro, Roberto Bianco, Luigi Formisano, Priscilla Cascetta, Pietro De Placido, Fabiana Napolitano, Ada Pesapane, Annachiara Carratù, Stefania Belli, Eleonora Mozzillo, Antonio Santaniello, Daniela Esposito
Publikováno v:
Cancer Research. 80:P3-06
Background: CDK4/6 inhibitors have been approved in combination with endocrine therapy for the treatment of estrogen receptor positive (ER+) metastatic breast cancer. The goal of this study was to discover mechanisms of resistance to ER antagonists a
Autor:
Marialucia Telesca, Anna De Vincenzo, Francesca Iommelli, Stefania Belli, Paolo Grieco, Diego Brancaccio, Marie Ranson, Alfonso Carotenuto, Paola Franco, Ettore Novellino, Francesco Merlino, Maria Patrizia Stoppelli, Silvana Del Vecchio
Publikováno v:
Cancers, Vol 12, Iss 2404, p 2404 (2020)
Cancers
Volume 12
Issue 9
Cancers (Basel) 12 (2020): 1–24. doi:10.3390/cancers12092404
info:cnr-pdr/source/autori:Belli S.; Franco P.; Iommelli F.; De Vincenzo A.; Brancaccio D.; Telesca M.; Merlino F.; Novellino E.; Ranson M.; Vecchio S.D.; Grieco P.; Carotenuto A.; Stoppelli M.P./titolo:Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides/doi:10.3390%2Fcancers12092404/rivista:Cancers (Basel)/anno:2020/pagina_da:1/pagina_a:24/intervallo_pagine:1–24/volume:12
Cancers
Volume 12
Issue 9
Cancers (Basel) 12 (2020): 1–24. doi:10.3390/cancers12092404
info:cnr-pdr/source/autori:Belli S.; Franco P.; Iommelli F.; De Vincenzo A.; Brancaccio D.; Telesca M.; Merlino F.; Novellino E.; Ranson M.; Vecchio S.D.; Grieco P.; Carotenuto A.; Stoppelli M.P./titolo:Breast tumor cell invasion and pro-invasive activity of cancer-associated fibroblasts co-targeted by novel urokinase-derived decapeptides/doi:10.3390%2Fcancers12092404/rivista:Cancers (Basel)/anno:2020/pagina_da:1/pagina_a:24/intervallo_pagine:1–24/volume:12
Among peritumoral cells, cancer-associated fibroblasts (CAFs) are major facilitators of tumor progression. This study describes the effects of two urokinase-derived, novel decapeptides, denoted as Pep 1 and its cyclic derivative Pep 2. In a mouse mod